|
WO2021066612A2
|
|
Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof
|
|
WO2021040496A1
|
|
Pharmaceutical composition for treating cancer, comprising vaccinia virus and granulopoiesis inhibitor as active ingredients
|
|
WO2020263059A1
|
|
Oncolytic virus with improved safety and anticancer effects
|
|
KR102216319B1
|
|
Pharmaceutical composition for treating systemic inflammation comprising hydroxyurea and formulation thereof
|
|
WO2021040065A1
|
|
Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients
|
|
WO2021040064A1
|
|
Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer
|
|
AU2019226906A1
|
|
Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components
|
|
KR20190080806A
|
|
Oncolytic virus with improved safety and anticancer effect
|
|
KR20190059421A
|
|
Methods for treatment of liver cancer using hepatic arterial administration of oncolytic virus
|
